• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

    7/1/24 8:00:00 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRUS alert in real time by email

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Fabian Zohren M.D., PhD as Chief Medical Officer (CMO) effective July 1, 2024. Andrew Joe, M.D. will step down from the CMO role and continue to serve as a Consultant for the next three months. In addition, effective July 1, Hui Liu, Ph.D., EVP, Chief Business Officer & Head of Merus U.S. is leaving Merus. The Company has initiated a search to find a replacement to head the business development function.

    "I am pleased to welcome Fabian Zohren to Merus as our new CMO and confident that his proven clinical development skills and late stage registrational trial experience will prove invaluable as we plan to initiate two phase 3 trials in 2024 for petosemtamab, and continue to build out a development strategy that maximizes the opportunity this important clinical candidate may have for patients," said Bill Lundberg, M.D., President, Chief Executive Officer of Merus. "I am grateful for Andrew's leadership particularly for guiding our most advanced clinical candidate Zeno through clinical development which has resulted in two Breakthrough Therapy Designations and the acceptance of our first Biologics License Application submission under priority review for NRG1+ non-small cell lung and NRG1+ pancreatic cancer–a key milestone for the evolution of our company. Andrew has also been instrumental in leading the development of petosemtamab, through the phase 1/2 trials, obtaining Breakthrough Therapy Designation, and planning of the phase 3 trials, and I'm thankful that he has agreed to stay on as an adviser during this important stage at Merus."

    Dr. Fabian Zohren is a proven late-stage clinical development expert, joining Merus from ImmunoGen where he was SVP and Chief Medical Officer from November 2023 through its acquisition by AbbVie in May 2024. Prior to ImmunoGen, Dr. Zohren worked at Pfizer from 2017 until 2023 where he most recently served as Global Clinical Development Leader for prostate cancer and DNA repair, a role which included Xtandi® (enzalutamide) and Talzenna® (talazoparib) with oversight of two clinical programs encompassing >8000 treated patients and 8 global phase 3 registrational studies in prostate and breast cancer. Earlier in his career at Pfizer, he was the Senior Medical Director and Global Clinical Leader for prostate cancer and gynecological malignancies. He joined Pfizer from Millennium Pharmaceuticals/Takeda where he was the Senior Medical Director and Early Clinical Development Leader for their Cell Signaling Franchise since 2012. Dr. Zohren received his Medical Degree and Ph.D. from the University of Dusseldorf and was a research scholar at Baylor College of Medicine in the Center for Cell and Gene Therapy.

    "I would also like to thank Hui for all of his contributions to Merus over the years," said Bill Lundberg, M.D., President, Chief Executive Officer of Merus. "In his role as Chief Business Officer, Hui has been essential to the Merus story - instrumental in securing the foundational platform collaborations that have been pivotal to funding our company through our earlier stages. And, as the first US based employee of Merus and Head of Merus US, he painstakingly set up the US office and helped grow the Merus US team to about 50 employees. Over a four and a half-year period, Hui built and led a top-notch finance team that is well positioned to support the growth of Merus to come."  

    About Merus N.V.  

    Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus' website, https://www.merus.nl and https://twitter.com/MerusNV.  

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the contributions that Dr. Zohren will make to the Company, including regarding the Company's plan to initiate two phase 3 trials in 2024 for petosemtamab, and continue to build out a development strategy that maximizes the potential opportunity this important clinical candidate may have for patients; the acceptance of our first Biologics License Application submission under priority review for NRG1+ non-small cell lung and NRG1+ pancreatic cancer, whether it may be approved and its impact for the Company. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our need for additional funding, which may not be available and which may require us to restrict our operations or require us to relinquish rights to our technologies or Biclonics®, Triclonics® and multispecific antibody candidates; potential delays in regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate revenue; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; the unpredictable nature of our early stage development efforts for marketable drugs; potential delays in enrollment of patients, which could affect the receipt of necessary regulatory approvals; our reliance on third parties to conduct our clinical trials and the potential for those third parties to not perform satisfactorily; impacts of the market volatility; we may not identify suitable Biclonics® or bispecific antibody candidates under our collaborations or our collaborators may fail to perform adequately under our collaborations; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and commercialization efforts; protection of our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors and our patent applications may be found not to comply with the rules and regulations of patentability; we may fail to prevail in potential lawsuits for infringement of third-party intellectual property; and our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.

    These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-Q for the quarter ended March 31, 2024 filed with the Securities and Exchange Commission, or SEC, on May 8, 2024, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

    Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V. 



    Investor and Media Inquiries:  
    Sherri Spear 
    Merus N.V. 
    VP Investor Relations and Corporate Communications 
    617-821-3246 
    [email protected]  
    
    Kathleen Farren  
    Merus N.V. 
    IR/Corp Comms 
    617-230-4165 
    [email protected]  

    Primary Logo

    Get the next $MRUS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRUS

    DatePrice TargetRatingAnalyst
    2/13/2025$84.00Overweight
    Piper Sandler
    2/7/2025$91.00Overweight
    Wells Fargo
    11/21/2024$73.00Buy
    Goldman
    10/24/2024$72.00Buy
    UBS
    3/28/2024$69.00Buy
    Truist
    3/4/2024$42.00 → $65.00Buy
    Needham
    11/2/2023$45.00Buy
    Canaccord Genuity
    8/21/2023Outperform
    TD Cowen
    More analyst ratings

    $MRUS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Merus to Present at BofA Securities 2025 Health Care Conference

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), an oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Thursday, May 15, 2025 at 8:40 a.m. PT/11:40 a.m. ET. The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event. About MerusMerus is an oncology company de

      5/8/25 8:00:00 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

      - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting - Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced financial results for the first quarter and provided a business update. "We are very muc

      5/7/25 4:11:44 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

      - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation - Conference call on Thursday, May 22 at 5:30 p.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the acceptance of an abstract for presentation at the 2025 American Society of Clinical Oncology® (ASCO®) Annual Meeting, being held in Chicago, Illinois on May 30- June 3, 202

      4/23/25 10:00:00 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • December 6, 2024 - FDA Roundup: December 6, 2024

      For Immediate Release: December 06, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA published the draft guidance, “Expedited Program for Serious Conditions — Accelerated Approval of Drugs and Biologics,” which proposes updates to certain agency policies and procedures regarding accelerated approval. Topics addressed by this

      12/6/24 3:09:02 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler initiated coverage on Merus with a new price target

      Piper Sandler initiated coverage of Merus with a rating of Overweight and set a new price target of $84.00

      2/13/25 8:09:56 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Merus with a new price target

      Wells Fargo initiated coverage of Merus with a rating of Overweight and set a new price target of $91.00

      2/7/25 8:26:14 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Merus with a new price target

      Goldman initiated coverage of Merus with a rating of Buy and set a new price target of $73.00

      11/21/24 7:35:31 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    Financials

    Live finance-specific insights

    See more
    • Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

      - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting - Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced financial results for the first quarter and provided a business update. "We are very muc

      5/7/25 4:11:44 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

      - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation - Conference call on Thursday, May 22 at 5:30 p.m. ET to discuss full ASCO® data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the acceptance of an abstract for presentation at the 2025 American Society of Clinical Oncology® (ASCO®) Annual Meeting, being held in Chicago, Illinois on May 30- June 3, 202

      4/23/25 10:00:00 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

      -  Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25 -  Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update planned for 1H25 -  Petosemtamab evaluation in mCRC ongoing in combination with standard chemotherapy in 1L and 2L and monotherapy in 3L+; mCRC initial clinical data planned for 2H25 -  Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2028 UTRECHT, The Netherla

      2/27/25 4:10:40 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, CEO & PEO Lundberg Sven Ante exercised 30,297 shares at a strike of $13.40 (SEC Form 4)

      4 - Merus N.V. (0001651311) (Issuer)

      4/21/25 4:05:04 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP Controller, PAO Shuman Harry converted options into 3,000 shares and sold $193,990 worth of shares (4,000 units at $48.50), decreasing direct ownership by 8% to 11,002 units (SEC Form 4)

      4 - Merus N.V. (0001651311) (Issuer)

      3/25/25 4:10:05 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP Controller, PAO Shuman Harry converted options into 5,000 shares, increasing direct ownership by 71% to 12,002 units (SEC Form 4)

      4 - Merus N.V. (0001651311) (Issuer)

      3/25/25 4:05:04 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Merus N.V.

      10-Q - Merus N.V. (0001651311) (Filer)

      5/7/25 4:05:27 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Merus N.V.

      DEF 14A - Merus N.V. (0001651311) (Filer)

      4/24/25 4:05:39 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Merus N.V.

      PRE 14A - Merus N.V. (0001651311) (Filer)

      4/14/25 4:15:27 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRUS
    Leadership Updates

    Live Leadership Updates

    See more
    • Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Fabian Zohren M.D., PhD as Chief Medical Officer (CMO) effective July 1, 2024. Andrew Joe, M.D. will step down from the CMO role and continue to serve as a Consultant for the next three months. In addition, effective July 1, Hui Liu, Ph.D., EVP, Chief Business Officer & Head of Merus U.S. is leaving Merus. The Company has initiated a search to find a replacement to head the business development f

      7/1/24 8:00:00 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Greg Perry as the Company's Chief Financial Officer (CFO). Additionally, Greg has been designated as the Company's principal financial officer, succeeding Bill Lundberg, M.D., in such role. In connection with his appointment as the Company's Chief Financial Officer, on June 14, 2023, Greg resigned from the Company's Board of Directors. "I am excited to welcome Greg as our CFO and look forward to drawing from his broad biotech e

      6/15/23 7:47:06 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a range of specialty markets, including oncology. "Shannon will be instrumental in advancing Merus' mission to become a commercial-stage company, further advancing the strategy for our lead clinical progr

      1/25/22 4:30:00 PM ET
      $INCY
      $MRUS
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $MRUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Merus N.V.

      SC 13G/A - Merus N.V. (0001651311) (Subject)

      11/14/24 4:05:20 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Merus N.V.

      SC 13G/A - Merus N.V. (0001651311) (Subject)

      11/14/24 1:34:01 PM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Merus N.V.

      SC 13G/A - Merus N.V. (0001651311) (Subject)

      11/14/24 8:54:46 AM ET
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care